Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase I

Universal IbogaineTSXV: IBO

1 Drug Candidate

Canadian biotech developing standardised ibogaine therapy protocols for opioid use disorder. Filed a Clinical Trial Application (CTA) with Health Canada for a Phase 1 clinical study. The company has undergone management restructuring and faces ongoing financing challenges.

Drug Pipeline

1

Ibogaine (OUD)

Ibogaine
Phase I
Opioid Use Disorder (OUD)

Standardised ibogaine therapy protocol for opioid use disorder. Clinical Trial Application filed with Health Canada.

Quick Facts

Type
Public Biotech
Ticker
TSXV: IBO
Lead Stage
Phase I
Website
Visit